Key Medicine Shortages – October 2022
Key Medicine Shortages – October 2022
Posted: Monday, October 3, 2022
Category - Medicines Update
GGC Medicines Update is a series of blogs with important medicines related messages relevant to all healthcare professionals across GGC.
Please note, Medicines Update blogs are correct at the time of publication.
Medicines Update blogs remain on the website for 4 years. If you would like a copy of a blog published more than 4 years ago, please contact ggc.medicines.update@nhs.scot.
Click here for a promotional poster on Medicines Update and here for an animation on the Communications subcommittee of ADTC responsible for the development of Medicines Update.
If you would like to contribute to Medicines Update, click here for a guide to blog writing. When you email the committee to discuss writing a blog, you will be sent a checklist to complete prior to submitting the blog for review.
Posted: Monday, October 3, 2022
Category - Medicines Update
Key Medicine Shortages – October 2022
Posted: Tuesday, September 27, 2022
Category - Medicines Update
MHRA Drug Safety Update September 2022
Posted: Tuesday, September 20, 2022
Category - Medicines Update
NHS Public Health Scotland advise giving paracetamol suspension 120mg/5ml (sugar free) at the time of MenB vaccination, or as soon as possible afterwards, in order to reduce the risk of the baby developing a fever.
Posted: Wednesday, September 14, 2022
Category - Medicines Update
Sodium hyaluronate eye drops are on the NHSGGC Adult Medicines Formulary restricted to use in severe dry eye only
Blink Intensive Tears® (sodium hyaluronate 0.2%) eye drops (containing a preservative) are considered the first line sodium hyaluronate preparation.
Eyeaze® 0.4% (sodium hyaluronate 0.4%) preservative free eye drops have been added to the NHSGGC Adult Medicines Formulary following a Formulary appeal.
Posted: Friday, September 9, 2022
Category - Medicines Update
HEPMA Update – September 2022
Posted: Friday, September 9, 2022
Category - Medicines Update
Clinical trials of sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated improvement in kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) with and without diabetes.
Posted: Friday, September 9, 2022
Category - Medicines Update
Guideline News August 2022
Posted: Wednesday, August 31, 2022
Category - Medicines Update
MHRA Drug Safety Update for August 2022
Posted: Monday, August 22, 2022
Category - Medicines Update
Key Medicine Shortages for August 2022
Posted: Wednesday, August 10, 2022
Category - Medicines Update
Guideline News for July 2022